advertisement
Abstract #69023 Published in IGR 18-1
Tafluprost Ophthalmic Solution 0.0015Â %: A Review in Glaucoma and Ocular Hypertension
Keating GMClinical Drug Investigation 2016; 36: 499-508
Tafluprost ophthalmic solution 0.0015Â % preserved with benzalkonium chloride (BAK) 0.001Â % is available in several Asian countries, including Japan. In pivotal trials, BAK-preserved tafluprost ophthalmic solution 0.0015Â % lowered intraocular pressure (IOP) more effectively than placebo in Asian patients with normal-tension glaucoma and was at least as effective as latanoprost ophthalmic solution 0.005Â % in Asian patients with primary open-angle glaucoma or ocular hypertension. In other prospective studies in Asian patients with glaucoma or ocular hypertension, tafluprost ophthalmic solution 0.0015Â % was at least as effective as latanoprost ophthalmic solution 0.005Â % or travoprost ophthalmic solution 0.004Â % in terms of IOP lowering, and was considered easier to use and/or store. The efficacy of tafluprost ophthalmic solution 0.0015Â % was maintained in the longer term. Tafluprost ophthalmic solution 0.0015Â % was generally well tolerated. In conclusion, BAK-preserved tafluprost ophthalmic solution 0.0015Â % remains a useful option for the treatment of Asian patients with glaucoma and ocular hypertension.
Full article
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
9.2.1 Ocular hypertension (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)
